Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients

被引：0

作者：

Johnson, Daniel Johnson H. ^{[1
]}

Lecagoonporn, Srisuda ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah ^{[1
]}

Uemura, Marc ^{[1
]}

Yee, Cassian ^{[1
]}

Amaria, Rodabe ^{[1
]}

Patel, Sapna ^{[1
]}

Tawbi, Hussein ^{[1
]}

Glitza, Isabella ^{[1
]}

Davies, Michael A. ^{[1
]}

Wong, Michael K. ^{[1
]}

Hwu, Wen-Jen ^{[1
]}

Hwu, Patrick ^{[1
]}

Overwijk, Willem ^{[1
]}

Diab, Adi ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P230

引用

页数：1

共 43 条

[31] Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma
Haymaker, Cara
Uemura, Marc
Murthy, Ravi
James, Marihella
Wang, Daqing
Brevard, Julie
Swann, Suzanne
Geib, James
Cornfeld, Mark
Chunduru, Srinivas
Agrawal, Sudhir
Yee, Cassian
Wargo, Jennifer
Amaria, Rodabe
Patel, Sapna
Tawbi, Hussein
Glitza, Isabella
Woodman, Scott
Hwu, Wen-Jen
Davies, Michael A.
Hwu, Patrick
Overwjik, Willem
Bernatchez, Chantale
Diab, Adi
CANCER RESEARCH, 2017, 77
[32] Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma-A single-arm, multicenter, phase II study.
Lian, Bin
Chen, Yu
Wu, Di
Luo, Zhiguo
Zou, Zhengyun
Jiang, Yu
Pan, Hongming
Fan, Qingxia
Zhao, Jianfu
Xu, Qing
Jiang, Renbing
Cui, Chuanliang
Wang, Xuan
Lou, Fang
Guo, Zhen
Si, Lu
Chi, Zhihong
Sheng, Xinan
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.
O'Hara, Mark H.
Wattenberg, Max Miller
Garrido-Laguna, Ignacio
O'Reilly, Eileen Mary
Yellin, Michael Jay
Keler, Tibor
Gargano, Michele Anne
Niles, Nick
Drees, Jeremy
Bose, Nandita
Iglesias, Jose Luis
Beatty, Gregory Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma
Chen, Yu
Zhang, Xiaoshi
Ding, Ya
Jiang, Yu
Chen, Jing
Pu, Xingxiang
Ren, Xiubao
Zhang, Weizhen
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[35] Phase I/II clinical trial to evaluate the safety and efficacy of a combination of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma.
vanderKolk, LE
Gerritsen, W
Baars, J
Jonkhoff, AR
vanOers, MHJ
BLOOD, 1997, 90 (10) : 2284 - 2284
[36] PHASE-I/II STUDY OF MURINE MONOCLONAL-ANTIBODY RICIN-A CHAIN (XOMA-ZYME-MEL) IMMUNOTOXIN PLUS CYCLOSPORINE-A (CYA) IN PATIENTS (PTS) WITH METASTATIC MALIGNANT-MELANOMA (M)
SELVAGGI, KJ
ERNSTOFF, MS
VLOCK, DR
GEMPERLEIN, M
ACKERMAN, S
KIRKWOOD, JM
CLINICAL RESEARCH, 1990, 38 (02): : A272 - A272
[37] Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy
Cohen, Roger
Fayette, Jerome
Posner, Marshall
Lefebvre, Gautier
Bauman, Jessica
Salas, Sebastien
Even, Caroline
Seiwert, Tanguy
Colevas, Dimitrios
Jimeno, Antonio
Saada, Esma
Burtness, Barbara
Andre, Pascale
Paturel, Carine
Bonnafous, Cecile
Soulie, Anne-Marie
Tirouvanziam-Martin, Anne
Zerbib, Robert
Boyer-Chammard, Agnes
CANCER RESEARCH, 2018, 78 (13)
[38] An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Fiedler, Walter
Montesinos, Pau
Schliemann, Christoph
Middeke, Jan
Vasu, Sumithira
Scholz, Christian W.
Esteve, Jordi
Mondal, Shoubhik
Rueter, Bjoern
Burkard, Ute
Osswald, Annika
Blum, William
HAEMATOLOGICA, 2022, 107 (12) : 2977 - 2982
[39] Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
Tawbi, Hussein Abdul-Hassan
Peng, Weiyi
Phillips, Suzanne
Milton, Denai R.
Amaria, Rodabe Navroze
Diab, Adi
Glitza, Isabella Claudia
Patel, Sapna Pradyuman
Wong, Michael K. K.
Yee, Cassian
McQuade, Jennifer Leigh
Tetzlaff, Michael T.
Lazar, Alexander J.
Shephard, Michael
Cain, Suzanne
Burton, Elizabeth M.
Hwu, Patrick
Davies, Michael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial
Ray-Coquard, I.
Cassier, P.
Chabaud, S.
Mehlen, P.
Bernet, A.
Le Bras, F.
Gheit, H.
Angel, C.
Mastier, C.
Ducarouge, B.
Rouge, T. De La Motte
Gladieff, L.
Floquet, A.
Fabbro, M.
Joly, F.
Gross, M. Provansal
Frenel, J-S.
Leary, A.
Perol, D.
Blay, J-Y.
ANNALS OF ONCOLOGY, 2021, 32 : S769 - S769

← 1 2 3 4 5 →